(Q34680250)

3 August 2017

Elliptinium: phase II study in advanced measurable breast cancer (English)

1 reference

3 August 2017

Treat J

1

1 reference

3 August 2017

Greenspan A

2

1 reference

3 August 2017

Rahman A

3

1 reference

3 August 2017

McCabe MS

4

1 reference

3 August 2017

Byrne PJ

5

1 reference

3 August 2017

1 July 1989

1 reference

Investigational New Drugs

3 August 2017

1 reference

3 August 2017

7

1 reference

3 August 2017

2-3

1 reference

3 August 2017

231-234

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00170864

3 August 2017

0 references

cites work

Drug-induced antibodies during 2-N-methyl-9-hydroxyellipticinium acetate (NSC-264137) treatment: schedule dependency and relationship to hemolysis

1 reference

12 December 2020

Phase I study of elliptinium (2-N-methyl-9-hydroxyellipticinium)

1 reference

12 December 2020

Alkaloids of Ochrosia maculata Jacq. (Ochrosia borbonica Gmel.). Isolation of the alkaloids and study of the antitumor properties of 9-methoxyellipticine

1 reference

12 December 2020

Hydroxy-9-methyl-2-ellipticinium for osseous metastases from breast cancer: a 5-year experience

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00170864

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference